Business
Operational update on Kirkstall Limited
Operational update on Kirkstall Limited.
About this update from Truetide Plc
[{"type":"text","content":"\n \n \n RNS Number : 5895O\n Braveheart Investment Group plc\n 02 June 2020\n \n \n \n \n RNS Reach announcement (non-regulatory)\n \n \n 2 June 2020\n \n \n Braveheart Investment Group plc\n \n \n (\"Braveheart\" or the \"Group\")\n \n \n Operational update on Kirkstall Limited\n \n \n Braveheart (AIM: BRH), the fund management and strategic investment group, is pleased to provide an operational update on its strategic investment Kirkstall Limited.\n \n \n \n \n \n Kirkstall Limited (\"Kirkstall\") (holding 80%)\n \n \n Further to the announcement on 23 April 2020, which reported that Kirkstall is now collaborating with Animal Free Research UK, the UK's leading non-animal medical research charity, awarding grants to research scientists to implement new and existing techniques to replace the use of animal in trials and research.\n \n \n Animal Free Research UK's assessment panel has awarded the first three projects that will use Kirkstall's Quasi Vivo® system in research related to COVID-19:\n \n \n \n \n \n 1. Dr Carolina Herrera, Imperial College London\n \n \n \n \n \n \n Project Title\n \n : Modelling early immune responses to SARS-CoV-2 in a fluidic system\n \n \n \n \n \n \n Dr Herrera's Project Description\n \n : \"To develop a model that mimics infection of SARS-CoV-2 taking into consideration the natural flow of lymph and blood in the body. With this model we want to assess the cellular responses to the entry of SARS-CoV-2 in cells from the respiratory tract and the effect of such responses on circulating blood cells from the immune system. We will be able to isolate the responses triggered by viral entry using a virus that cannot replicate in the infected cell. We will also test drug candidates for their potential to inhibit the first steps of infection and therefore the first stage of the inflammation process.\n \n \n \n \n \n \"The Kirkstall system allows us to measure the number of infected cells and their responses to the infection; and at the same time to observe the consequences of the infection on blood cells that are circulating, mimicking what happens in the human body.\"\n \n 2. Dr Mark Turner, Centre for Sport, Exercise and Life Sciences, Coventry University\n \n \n \n \n \n \n Project Title:\n \n A human-relevant system to investigate obesity, diabetes ...